{
  "symbol": "GILD",
  "year": 2022,
  "Period": "Q2",
  "report_type": "Q10",
  "metrics": {
    "mdna_sentiment": 0.0,
    "outlook_sentiment": 0.0817,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.323
  },
  "top_positive": [
    {
      "sent": "The following table summarizes the classification and fair values of derivative instruments in our Condensed Consolidated Balance Sheets: June 30, 2022 Derivative Assets Derivative Liabilities (in millions) Classification Fair Value Classification Fair Value Derivatives designated as hedges: Foreign currency exchange contracts Prepaid and other current assets $ 123 Accrued and other current liabilities $ \u2014 Foreign currency exchange contracts Other long-term assets 9 Other\u00a0long-term\u00a0obligations \u2014 Total derivatives designated as hedges 132 \u2014 Derivatives not designated as hedges: Foreign currency exchange contracts Prepaid and other current assets 4 Accrued and other current liabilities 2 Total derivatives not designated as hedges 4 2 Total derivatives $ 136 $ 3 15 December 31, 2021 Derivative Assets Derivative Liabilities (in millions) Classification Fair Value Classification Fair Value Derivatives designated as hedges: Foreign currency exchange contracts Prepaid and other\u00a0current\u00a0assets $ 75 Accrued and other current liabilities $ 4 Foreign currency exchange contracts Other\u00a0long-term\u00a0assets 5 Other\u00a0long-term\u00a0obligations 1 Total derivatives designated as hedges 80 5 Derivatives not designated as hedges: Foreign currency exchange contracts Prepaid and other\u00a0current\u00a0assets \u2014 Accrued and other current liabilities \u2014 Total derivatives not designated as hedges \u2014 \u2014 Total derivatives $ 80 $ 5 The following table summarizes the effect of our foreign currency exchange contracts on our Condensed Consolidated Financial Statements: Three Months Ended Six Months Ended June 30, June 30, (in millions) 2022 20\nllions) June 30, 2022 December 31, 2021 Cash and cash equivalents $ 29 $ 6 Short-term marketable debt securities 924 1,182 Long-term marketable debt securities 1,337 1,309 Total $ 2,290 $ 2,497 The following table summarizes our available-for-sale debt securities by contractual maturity: June 30, 2022 (in millions) Amortized\u00a0Cost Fair Value Within one year $ 962 $ 953 After one year through five years 1,338 1,313 After five years through ten years 15 15 After ten years 9 8 Total $ 2,324 $ 2,290 Equity Securities Equity Securities Measured at Fair Value The following table summarizes the classification of our equity securities measured at fair value on a recurring basis, including our equity method investments in Galapagos and Arcus for which we elected and applied the fair value option as we believe it best reflects the underlying economics of these investments, on our Condensed Consolidated Balance Sheets: (in millions) June 30, 2022 December 31, 2021 Cash and cash equivalents $ 3,094 $ 3,661 Prepaid and other current assets 477 885 Other long-term assets 1,140 1,197 Total $ 4,711 $ 5,743 Other Equity Securities Equity method investments and other equity investments without readily determinable fair values were $ 359 million and $ 338 million as of June\u00a030, 2022 and December\u00a031, 2021, respectively, and were included in Other long-term assets on our Condensed Consolidated Balance Sheets.",
      "score": 0.9951
    },
    {
      "sent": "2022 Equity Incentive Plan (13) 10.4* Form of employee stock option agreement under 2004 Equity Incentive Plan (for grants made in 2011 through 2018) (14) 10.5* Form of employee stock option agreement under 2004 Equity Incentive Plan (for grants made in 2019) (15) 10.6* Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for grants made in 2019) (16) 10.7* Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for grants made in 2020) (17) 10.8* Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for grants made in 2021) (18) 10.9* Form of gl",
      "score": 0.9889
    },
    {
      "sent": "The following table summarizes the classification of our available-for-sale debt securities in our Condensed Consolidated Balance Sheets: (in millions) June 30, 2022 December 31, 2021 Cash and cash equivalents $ 29 $ 6 Short-term marketable debt securities 924 1,182 Long-term marketable debt securities 1,337 1,309 Total $ 2,290 $ 2,497 The following table summarizes our available-for-sale debt securities by contractual maturity: June 30, 2022 (in millions) Amortized\u00a0Cost Fair Value Within one year $ 962 $ 953 After one year through five years 1,338 1,313 After five years through ten years 15 15 After ten years 9 8 Total $ 2,324 $ 2,290 Equity Securities Equity Securities Measured at Fair Value The following table summarizes the classification of our equity securities measured at fair value on a recurring basis, including our equity method investments in Galapagos and Arcus for which we elected and applied the fair value option as we believe it best reflects the underlying economics of these investments, on our Condensed Consolidated Balance Sheets: (in millions) June 30, 2022 December 31, 2021 Cash and cash equivalents $ 3,094 $ 3,661 Prepaid and other current assets 477 885 Other long-term assets 1,140 1,197 Total $ 4,711 $ 5,743 Other Equity Securities Equity method investments and other equity investments without readily determinable fair values were $ 359 million and $ 338 million as of June\u00a030, 2022 and December\u00a031, 2021, respectively, and were included in Other long-term assets on our Condensed Consolidated Balance Sheets.",
      "score": 0.9875
    }
  ],
  "top_negative": [
    {
      "sent": "Oncology \u2022 In August 2022, we received updated National Comprehensive Cancer Network (\u201cNCCN\u201d) recommendations for sacituzumab govitecan-hziy to a category 1 preferred recommendation in second-line and later metastatic triple-negative breast cancer (\u201cTNBC\u201d) and was added as a category 2A preferred recommendation in the investigational indication of HR+/HER2- advanced breast cancer by the NCCN Guidelines \u00ae for Breast Cancer.",
      "score": -0.9485
    },
    {
      "sent": "Problems with any of the single suppliers or facilities we depend on, including in the event of a disaster, such as an earthquake, equipment failure or other difficulty, may negatively impact our development and commercialization efforts.",
      "score": -0.91
    },
    {
      "sent": "Problems with any of the single suppliers or facilities we depend on, including in the event of a disaster, such as an earthquake, equipment failure or other difficulty, may negatively impact our development and commercialization efforts.",
      "score": -0.91
    }
  ],
  "forward_snippets": [
    "We believe this presentation assists users of the financial statements to better understand the total costs incurred to acquire in-process research and development (\u201cIPR&D\u201d) projects.",
    "No allowance for credit losses was recognized for investments with unrealized losses as of June\u00a030, 2022, as we do not currently intend to sell, and it is not more likely than not that we will be required to sell, such investments before recovery of their amortized cost bases.",
    "The following table summarizes the classification of our available-for-sale debt securities in our Condensed Consolidated Balance Sheets: (in millions) June 30, 2022 December 31, 2021 Cash and cash equivalents $ 29 $ 6 Short-term marketable debt securities 924 1,182 Long-term marketable debt securities 1,337 1,309 Total $ 2,290 $ 2,497 The following table summarizes our available-for-sale debt securities by contractual maturity: June 30, 2022 (in millions) Amortized\u00a0Cost Fair Value Within one year $ 962 $ 953 After one year through five years 1,338 1,313 After five years through ten years 15 15 After ten years 9 8 Total $ 2,324 $ 2,290 Equity Securities Equity Securities Measured at Fair Value The following table summarizes the classification of our equity securities measured at fair value on a recurring basis, including our equity method investments in Galapagos and Arcus for which we elected and applied the fair value option as we believe it best reflects the underlying economics of these investments, on our Condensed Consolidated Balance Sheets: (in millions) June 30, 2022 December 31, 2021 Cash and cash equivalents $ 3,094 $ 3,661 Prepaid and other current assets 477 885 Other long-term assets 1,140 1,197 Total $ 4,711 $ 5,743 Other Equity Securities Equity method investments and other equity investments without readily determinable fair values were $ 359 million and $ 338 million as of June\u00a030, 2022 and December\u00a031, 2021, respectively, and were included in Other long-term assets on our Condensed Consolidated Balance Sheets.",
    "The following table summarizes the classification and fair values of derivative instruments in our Condensed Consolidated Balance Sheets: June 30, 2022 Derivative Assets Derivative Liabilities (in millions) Classification Fair Value Classification Fair Value Derivatives designated as hedges: Foreign currency exchange contracts Prepaid and other current assets $ 123 Accrued and other current liabilities $ \u2014 Foreign currency exchange contracts Other long-term assets 9 Other\u00a0long-term\u00a0obligations \u2014 Total derivatives designated as hedges 132 \u2014 Derivatives not designated as hedges: Foreign currency exchange contracts Prepaid and other current assets 4 Accrued and other current liabilities 2 Total derivatives not designated as hedges 4 2 Total derivatives $ 136 $ 3 15 December 31, 2021 Derivative Assets Derivative Liabilities (in millions) Classification Fair Value Classification Fair Value Derivatives designated as hedges: Foreign currency exchange contracts Prepaid and other\u00a0current\u00a0assets $ 75 Accrued and other current liabilities $ 4 Foreign currency exchange contracts Other\u00a0long-term\u00a0assets 5 Other\u00a0long-term\u00a0obligations 1 Total derivatives designated as hedges 80 5 Derivatives not designated as hedges: Foreign currency exchange contracts Prepaid and other\u00a0current\u00a0assets \u2014 Accrued and other current liabilities \u2014 Total derivatives not designated as hedges \u2014 \u2014 Total derivatives $ 80 $ 5 The following table summarizes the effect of our foreign currency exchange contracts on our Condensed Consolidated Financial Statements: Three Months Ended Six Months Ended June 30, June 30, (in millions) 2022 20\nllions) June 30, 2022 December 31, 2021 Cash and cash equivalents $ 29 $ 6 Short-term marketable debt securities 924 1,182 Long-term marketable debt securities 1,337 1,309 Total $ 2,290 $ 2,497 The following table summarizes our available-for-sale debt securities by contractual maturity: June 30, 2022 (in millions) Amortized\u00a0Cost Fair Value Within one year $ 962 $ 953 After one year through five years 1,338 1,313 After five years through ten years 15 15 After ten years 9 8 Total $ 2,324 $ 2,290 Equity Securities Equity Securities Measured at Fair Value The following table summarizes the classification of our equity securities measured at fair value on a recurring basis, including our equity method investments in Galapagos and Arcus for which we elected and applied the fair value option as we believe it best reflects the underlying economics of these investments, on our Condensed Consolidated Balance Sheets: (in millions) June 30, 2022 December 31, 2021 Cash and cash equivalents $ 3,094 $ 3,661 Prepaid and other current assets 477 885 Other long-term assets 1,140 1,197 Total $ 4,711 $ 5,743 Other Equity Securities Equity method investments and other equity investments without readily determinable fair values were $ 359 million and $ 338 million as of June\u00a030, 2022 and December\u00a031, 2021, respectively, and were included in Other long-term assets on our Condensed Consolidated Balance Sheets.",
    "We believe the \u2019830 patent is invalid and will not be infringed by the continued commercialization of sofosbuvir."
  ]
}